Demars Financial Group LLC Takes $907,000 Position in Novo Nordisk A/S $NVO

Demars Financial Group LLC bought a new stake in Novo Nordisk A/S (NYSE:NVO) in the third quarter, Holdings Channel reports. The institutional investor bought 16,339 shares of the company’s stock, valued at approximately $907,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Revolve Wealth Partners LLC raised its stake in shares of Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after buying an additional 200 shares in the last quarter. AQR Capital Management LLC raised its position in Novo Nordisk A/S by 21.0% in the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after purchasing an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC raised its position in Novo Nordisk A/S by 18.2% in the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after purchasing an additional 1,587 shares in the last quarter. Park Avenue Securities LLC bought a new position in Novo Nordisk A/S during the second quarter worth about $5,934,000. Finally, U.S. Capital Wealth Advisors LLC boosted its holdings in Novo Nordisk A/S by 447.0% during the second quarter. U.S. Capital Wealth Advisors LLC now owns 47,988 shares of the company’s stock valued at $3,312,000 after purchasing an additional 39,215 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a report on Wednesday, January 14th. HSBC reiterated a “hold” rating and set a $54.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, January 9th. Hsbc Global Res cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. Finally, CICC Research started coverage on shares of Novo Nordisk A/S in a report on Friday, January 9th. They set an “outperform” rating and a $73.50 price target for the company. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $56.21.

Novo Nordisk A/S Stock Down 2.6%

Shares of NYSE:NVO opened at $60.70 on Wednesday. The company has a quick ratio of 0.57, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The firm has a market cap of $271.00 billion, a P/E ratio of 17.64 and a beta of 0.66. Novo Nordisk A/S has a 12 month low of $43.08 and a 12 month high of $93.80. The company’s 50-day moving average price is $51.41 and its two-hundred day moving average price is $54.76.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The company had revenue of $11.79 billion during the quarter, compared to the consensus estimate of $11.98 billion. As a group, research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.